Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study.

ABSTRACT: Background:Helicobacter pylori infection has been associated with insulin resistance and non-alcoholic fatty liver disease (NAFLD). This study was done to evaluate the effect of H. pylori-eradication therapy (HPET) in patients with NAFLD compared to standard management therapy (SMT). Methods:Eighty NAFLD patients with H. pylori co-infection were randomized into SMT (diet and exercise, n?=?36) and HPET (SMT plus amoxicillin, clarithromycin, and pantoprazole, n?=?44) groups. The controlled attenuation parameter (CAP), anthropometric parameters, liver enzymes, lipid profile, and glycemic parameters including homeostasis model assessment-insulin resistance (HOMA-IR) were measured and compared between two groups at the baseline and 24?weeks. Results:Sixty-four participants (SMT group [n?=?28] and HPET group [n?=?36]) were included in a modified intention-to-treat analysis. Both the SMT group and the HPET group had a significant reduction in CAP scores at 24?weeks (P?=?0.002 and P?

SUBMITTER: Maharshi V 

PROVIDER: S-EPMC7261206 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature